News
Article
On November 19, the FDA granted traditional approval to tarlatamab-dlle for adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
For more information, read the FDA announcement and the Amgen press release.
Posted on 11/21/2025